PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-20.79%
Negative net income growth while CSIQ stands at 4.97%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
12.37%
D&A growth of 12.37% while CSIQ is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
86.60%
Deferred tax of 86.60% while CSIQ is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
1.63%
SBC growth of 1.63% while CSIQ is zero at 0.00%. Bruce Berkowitz would see some additional share issuance that must be justified by expansions or retention needs.
316.12%
Working capital change of 316.12% while CSIQ is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might affect near-term cash flow.
No Data
No Data available this quarter, please select a different quarter.
168.93%
Inventory growth of 168.93% while CSIQ is zero at 0.00%. Bruce Berkowitz would see a moderate build that must match future sales to avoid risk.
No Data
No Data available this quarter, please select a different quarter.
382.76%
Growth of 382.76% while CSIQ is zero at 0.00%. Bruce Berkowitz would see a difference in minor WC usage that might affect short-term cash flow if large.
-184.08%
Both negative yoy, with CSIQ at -4.97%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
391.18%
CFO growth of 391.18% while CSIQ is zero at 0.00%. Bruce Berkowitz would see a modest edge that could widen if cost discipline remains strong.
-24.69%
Negative yoy CapEx while CSIQ is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
146.16%
Purchases growth of 146.16% while CSIQ is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
-68.20%
We reduce yoy sales while CSIQ is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
-228.35%
We reduce yoy other investing while CSIQ is 0.00%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
-664.33%
We reduce yoy invests while CSIQ stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative yoy issuance while CSIQ is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
-92.91%
We cut yoy buybacks while CSIQ is 0.00%. Joel Greenblatt would question if competitor is gaining a per-share edge unless expansions justify holding cash here.